Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Germline RBBP8 variants associated with early-onset breast cancer compromise replication fork stability

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Thomas P Ahern
  • Per Damkier
  • Søren Feddersen
  • Anders Kjærsgaard
  • Timothy L Lash
  • Stephen Hamilton-Dutoit
  • Cathrine Bredal Lythjohan
  • Bent Ejlertsen
  • Peer M Christiansen
  • Deirdre P Cronin-Fenton
Vis graf over relationer

Background: Statins treat hyperlipidemia and prevent cardiovascular morbidity and mortality. Evidence suggests that they also have anti-neoplastic activity. Several studies show a reduced rate of breast cancer recurrence among lipophilic statin users (e.g., simvastatin), motivating calls for clinical trials of statins in breast cancer patients. We measured the impact of genetic variation in statin-metabolizing enzymes and drug transporters on the recurrence rate in simvastatin-treated breast cancer patients.Methods: We conducted a nested case-control study among Danish women diagnosed with non-metastatic, invasive breast cancer between 2004-2010 who had filled ≥1 prescription for simvastatin after diagnosis. Cases were all breast cancer recurrences from the source population; one control was matched to each case on cancer stage, estrogen receptor and hormone therapy status, calendar period of diagnosis, and duration of simvastatin exposure. We genotyped variants in simvastatin-metabolizing enzymes (CYP3A4/rs35599367 and CYP3A5/rs776746) and drug transporters (ABCB1/rs2032582 and SLCO1B1/rs4149056), and estimated their association with recurrence with logistic regression models.Results: We observed protective (though imprecisely-measured) associations between variants in genes encoding drug transporters (ABCB1 and SLCO1B1) and simvastatin-metabolizing enzymes (CYP3A4 and CYP3A5) and breast cancer recurrence in simvastatin-treated women. For example, carrying two variant alleles in ABCB1 was associated with a 31% lower rate of recurrence (multivariable OR = 0.69, 95% CI: 0.31, 1.5).Conclusion: Our study provides weak evidence to support the use of genetic variation in ABCB1, SLCO1B1, CYP3A4, and CYP3A5 as biomarkers of breast tumor response to simvastatin. Validation of these findings within adjuvant clinical trials is encouraged.

OriginalsprogEngelsk
TidsskriftActa Oncologica
Vol/bind59
Udgave nummer9
Sider (fra-til)1009-1015
Antal sider7
ISSN0284-186X
DOI
StatusUdgivet - sep. 2020

ID: 61370077